A phase I, open‐label, single‐dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib
Abstract Futibatinib is a covalently binding FGFR1–4 inhibitor that received US Food and Drug Administration approval for the treatment of patients with previously treated, advanced intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions/rearrangements. This phase I trial evaluated the pharmaco...
Main Authors: | Ling Gao, Ikuo Yamamiya, Mark Pinti, Juan Carlos Rondon, Thomas Marbury, Gareth Tomlinson, Lukas Makris, Nanae Hangai, Volker Wacheck |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-09-01
|
Series: | Clinical and Translational Science |
Online Access: | https://doi.org/10.1111/cts.13585 |
Similar Items
-
Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma
by: Jerry T. Wu, et al.
Published: (2023-08-01) -
Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer
by: Turcin Saridogan, et al.
Published: (2023-11-01) -
Dose adjustment not required for contezolid in patients with moderate hepatic impairment based on pharmacokinetic/pharmacodynamic analysis
by: Junzhen Wu, et al.
Published: (2023-03-01) -
Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling
by: Dhananjay D. Marathe, et al.
Published: (2023-10-01) -
The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib.
by: Horak, J, et al.
Published: (2011)